High-flying Indian generics-maker Sun Pharmaceutical says it expects copycat companies to find themselves in the same uncomfortable position as cliff-hanging drug innovators are today beginning in 2015. Prepare for a struggle as fewer new treatments hit the market with their patent clocks ticking, says Sun chairman and managing director Dilip Shanghvi. His guidance: Copy what innovator drug companies do, not just what they make. Story